Literature DB >> 28229579

Decitabine in TP53-Mutated AML.

Koichi Takahashi1, Guillermo Garcia-Manero1,2.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28229579     DOI: 10.1056/NEJMc1616062

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Classification and risk assessment in AML: integrating cytogenetics and molecular profiling.

Authors:  Matahi Moarii; Elli Papaemmanuil
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

2.  Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).

Authors:  Seongseok Yun; Susan M Geyer; Rami S Komrokji; Najla H Al Ali; Jinming Song; Mohammad Hussaini; Kendra L Sweet; Jeffrey E Lancet; Alan F List; Eric Padron; David A Sallman
Journal:  Leukemia       Date:  2020-07-29       Impact factor: 11.528

3.  Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.

Authors:  Bingshan Liu; Roshni Narurkar; Madhura Hanmantgad; Wahib Zafar; Yongping Song; Delong Liu
Journal:  Front Med       Date:  2018-05-21       Impact factor: 4.592

4.  TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Authors:  David A Sallman; Amy F McLemore; Amy L Aldrich; Rami S Komrokji; Kathy L McGraw; Abhishek Dhawan; Susan Geyer; Hsin-An Hou; Erika A Eksioglu; Amy Sullivan; Sarah Warren; Kyle J MacBeth; Manja Meggendorfer; Torsten Haferlach; Steffen Boettcher; Benjamin L Ebert; Najla H Al Ali; Jeffrey E Lancet; John L Cleveland; Eric Padron; Alan F List
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

5.  Prognostic significance of the tumor suppressor protein p53 gene in childhood acute lymphoblastic leukemia.

Authors:  Wenwen Weng; Ping Zhang; Jinfei Ruan; Yao Zhang; Diandian Ba; Yongmin Tang
Journal:  Oncol Lett       Date:  2019-11-07       Impact factor: 2.967

Review 6.  A precision medicine approach to management of acute myeloid leukemia in older adults.

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Vijaya Raj Bhatt
Journal:  Curr Opin Oncol       Date:  2020-11       Impact factor: 3.915

Review 7.  Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Cancers (Basel)       Date:  2018-05-24       Impact factor: 6.639

8.  Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.

Authors:  Moe Tamura; Taishi Yonezawa; Xiaoxiao Liu; Shuhei Asada; Yasutaka Hayashi; Tomofusa Fukuyama; Yosuke Tanaka; Toshio Kitamura; Susumu Goyama
Journal:  Sci Rep       Date:  2019-06-03       Impact factor: 4.379

9.  Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.

Authors:  Woonbok Chung; Andrew D Kelly; Patricia Kropf; Henry Fung; Jaroslav Jelinek; Xiang Yao Su; Gail J Roboz; Hagop M Kantarjian; Mohammad Azab; Jean-Pierre J Issa
Journal:  Clin Epigenetics       Date:  2019-07-22       Impact factor: 6.551

Review 10.  Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia.

Authors:  Carmelo Gurnari; Simona Pagliuca; Valeria Visconte
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.